{"id":"https://openalex.org/W2145063333","doi":"https://doi.org/10.2174/1389450115666141125123003","title":"EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies","display_name":"EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies","alternate_titles":[],"publication_year":2014,"publication_date":"2014-11-28","ids":{"openalex":"https://openalex.org/W2145063333","doi":"https://doi.org/10.2174/1389450115666141125123003","mag":"2145063333","pmid":"https://pubmed.ncbi.nlm.nih.gov/25429712"},"language":"en","primary_location":{"id":"doi:10.2174/1389450115666141125123003","doi":"https://doi.org/10.2174/1389450115666141125123003","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1389450115666141125123003","pdf_url":null,"source":{"id":"https://openalex.org/S140884253","display_name":"Current Drug Targets","issn_l":"1389-4501","issn":["1389-4501","1873-5592"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Drug Targets","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2145063333"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059114938","display_name":"Reza Nedaeinia","orcid":"https://orcid.org/0000-0001-9922-7181","observed_orcids":["https://orcid.org/0000-0001-9922-7181"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Reza Nedaeinia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103764849","display_name":"Amir Avan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Amir Avan","raw_affiliation_strings":["Medical oncology laboratory"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical oncology laboratory","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065156020","display_name":"Mostafa Manian","orcid":"https://orcid.org/0000-0001-7575-442X","observed_orcids":["https://orcid.org/0000-0001-7575-442X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mostafa Manian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101793490","display_name":"Rasoul Salehi","orcid":"https://orcid.org/0000-0003-4062-6166","observed_orcids":["https://orcid.org/0000-0003-4062-6166","https://orcid.org/0000-0002-1868-1735"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rasoul Salehi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5100611777","display_name":"Majid Ghayour\u2010Mobarhan","orcid":"https://orcid.org/0000-0002-1081-6754","observed_orcids":["https://orcid.org/0000-0002-1081-6754","https://orcid.org/0000-0001-5947-8904","https://orcid.org/0000-0002-2482-2450","https://orcid.org/0000-0003-2852-7632","https://orcid.org/0000-0003-4088-0308","https://orcid.org/0000-0002-9319-9957"]},"institutions":[{"id":"https://openalex.org/I165560825","display_name":"Mashhad University of Medical Sciences","ror":"https://ror.org/04sfka033","country_code":"IR","type":"education","lineage":["https://openalex.org/I165560825"]}],"countries":["IR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Majid Ghayour-Mobarhan","raw_affiliation_strings":["Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran.,Iran","Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran.,Iran","institution_ids":["https://openalex.org/I165560825"]},{"raw_affiliation_string":"Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran","institution_ids":["https://openalex.org/I165560825"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.9379,"has_fulltext":false,"cited_by_count":64,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.86051659,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":"15","issue":"14","first_page":"1293","last_page":"1301"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10760","display_name":"Pancreatitis Pathology and Treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.7089999914169312},{"id":"https://openalex.org/keywords/pancreatic-ductal-adenocarcinoma","display_name":"pancreatic ductal adenocarcinoma","score":0.9739999771118164},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.9490000009536743},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.8980000019073486},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.828000009059906},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7110000252723694},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6830000281333923},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8299999833106995},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.7770000100135803},{"id":"https://openalex.org/keywords/signaling-crosstalk","display_name":"signaling crosstalk","score":0.7940000295639038}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9240201711654663},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7945652604103088},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.7630441784858704},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.7065025568008423},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.6605777144432068},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.6301614046096802},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5411607027053833},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.524926483631134},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.44895681738853455},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.4153464436531067},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3850516974925995},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3839266300201416},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3790717124938965}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D021441","descriptor_name":"Carcinoma, Pancreatic Ductal","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D021441","descriptor_name":"Carcinoma, Pancreatic Ductal","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.2174/1389450115666141125123003","doi":"https://doi.org/10.2174/1389450115666141125123003","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1389450115666141125123003","pdf_url":null,"source":{"id":"https://openalex.org/S140884253","display_name":"Current Drug Targets","issn_l":"1389-4501","issn":["1389-4501","1873-5592"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Drug Targets","raw_type":"journal-article"},{"id":"pmid:25429712","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25429712","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current drug targets","raw_type":"Journal Article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/ca425480-f3e3-41e5-8dbf-9fbeb34bf4f6","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/ca425480-f3e3-41e5-8dbf-9fbeb34bf4f6","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nedaeinia, R, Avan, A, Manian, M, Salehi, R & Ghayour-Mobarhan, M 2014, 'EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies', Current drug targets, vol. 15, no. 14, pp. 1293-1301. https://doi.org/10.2174/1389450115666141125123003","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/af359508-4076-4233-9f44-0b39f5ae73c3","doi":null,"is_oa":false,"landing_page_url":"https://research.vumc.nl/en/publications/af359508-4076-4233-9f44-0b39f5ae73c3","pdf_url":null,"source":{"id":"https://openalex.org/S7407055350","display_name":"Amsterdam UMC (VU Amsterdam) - Institutional Repository","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nedaeinia, R, Avan, A, Manian, M, Salehi, R & Ghayour-Mobarhan, M 2014, 'EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies', Current Drug Targets, vol. 15, no. 14, pp. 1293-1301. https://doi.org/10.2174/1389450115666141125123003","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:vumc:oai:pure.atira.dk:publications/af359508-4076-4233-9f44-0b39f5ae73c3","doi":null,"is_oa":false,"landing_page_url":"https://research.vumc.nl/en/publications/af359508-4076-4233-9f44-0b39f5ae73c3","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Current Drug Targets, 15(14), 1293 - 1301. Bentham Science Publishers B.V.","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2108753213","https://openalex.org/W2418244451","https://openalex.org/W2156246262","https://openalex.org/W2095327431","https://openalex.org/W2167157100","https://openalex.org/W1993522242","https://openalex.org/W1805832649","https://openalex.org/W7095797933","https://openalex.org/W2163866397"],"abstract_inverted_index":{"Pancreatic":[0],"Ductal":[1],"Adenocarcinoma":[2],"(PDAC)":[3],"is":[4],"among":[5],"the":[6,22,30,38,49,82,93,100,160,165,195,211,224,244],"most":[7,33,185],"lethal":[8],"solid":[9],"tumors":[10],"with":[11,77,103,109,119,134],"grim":[12],"prognosis.":[13],"This":[14],"dismal":[15],"outcome":[16],"can":[17],"partially":[18],"be":[19,240],"explained":[20],"by":[21],"resistance":[23,219],"to":[24,91,142,207,218,220,242],"currently":[25],"available":[26,67],"chemotherapy":[27],"regimens":[28],"or":[29],"failure":[31],"of":[32,40,48,56,73,85,95,116,124,132,153,167,172,177,198,210,213,226,248],"anticancer":[34,250],"agents,":[35],"which":[36],"prompted":[37],"development":[39,171,197],"new":[41],"and":[42,112,127,150,164,179,215,228,233,246],"effective":[43],"therapeutic-approaches,":[44],"such":[45],"as":[46,97,99],"inhibitors":[47,59,118],"epidermal":[50],"growth":[51],"factor":[52],"receptor":[53],"(EGFR).":[54],"Some":[55],"these":[57],"EGFR":[58,86,117,199,221,232,253],"(e.g.,":[60],"erlotinib)":[61],"are":[62,69,184,205],"approved":[63],"for":[64,71,194],"lungcancer,":[65],"however":[66],"data":[68],"inconclusive":[70],"treatment":[72],"pancreatic":[74,255],"cancer":[75],"patients":[76,182],"EGFR-targeted-therapies.":[78],"Here":[79],"we":[80],"describe":[81],"critical":[83,241],"role":[84],"pathway":[87],"in":[88,139,254],"pancreatic-cancer,":[89],"strategies":[90,251],"enhance":[92],"effectiveness":[94],"EGFRinhibitors":[96],"well":[98],"preclinical/clinical":[101,203],"studies":[102,204,238],"particular":[104],"emphasis":[105],"on":[106],"recent":[107],"findings":[108],"monoclonal":[110],"antibodies":[111],"tyrosine-inhibitors.":[113],"Several":[114],"combinations":[115],"other":[120],"agents":[121],"illustrate":[122],"inhibition":[123],"tumor-induced":[125],"angiogenesis":[126],"cell":[128],"growth.":[129],"Moreover,":[130],"combination":[131],"erlotinib":[133],"gemcitabine":[135],"showed":[136],"statistically":[137],"significance":[138],"overall-survival,":[140],"compared":[141],"gemcitabine-alone.":[143],"However":[144],"high":[145],"cost,":[146],"little":[147],"survival":[148],"gain":[149],"increased":[151],"risk":[152],"toxicities":[154],"have":[155],"limited":[156],"its":[157],"efficacy.":[158],"Considering":[159],"multiple":[161,173],"genetic":[162,227],"mutations":[163],"crosstalk":[166],"signaling":[168],"pathways,":[169],"(1)":[170],"targeted-therapies;":[174],"(2)":[175],"identification":[176],"predictive-biomarkers;":[178],"(3)":[180],"those":[181],"who":[183],"likely":[186],"benefit":[187],"from":[188],"therapy,":[189],"could":[190],"provide":[191],"valuable":[192],"direction":[193],"clinical":[196],"inhibitors.":[200],"Moreover":[201],"further":[202],"warranted":[206],"identify":[208],"determinants":[209],"activity":[212],"EGFR-inhibitors":[214],"mechanisms":[216],"leading":[217],"inhibitors,":[222],"through":[223],"analysis":[225],"environmental":[229],"alterations":[230],"affecting":[231],"parallel":[234],"pro-cancer":[235],"pathways.":[236],"These":[237],"will":[239],"improve":[243],"efficacy":[245],"selectivity":[247],"current":[249],"targeting":[252],"cancer.":[256]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2145063333","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":7},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
